To determine features of the bone metabolism, 65 patients with prostate cancer (PC) were examined. Locally advanced process is determined in 41 patients, disseminated counterpart – in 24 patients. To specify the level of bone metabolism, the level of the osteoporosis markers – osteocalcin and â-cross-laps was measured. The markers level determines activity of the bone metabolism: osteocalcin shows the level of synthesis, â-cross-laps – resorbtion intensity. In locally advanced PC, a significant positive correlation between resorbtion marker and the patients age is observed. An increase in the value of the marker of bone synthesis and time of treatment after surgical castration in patients with locally advanced process is observed. Thus, increase of the bone metabolism is revealed, reliably associated with the age changes and the treatment features in patients with locally advanced PC. The same changes accompany metastatic cancer progression. Based on these observations, the one can conclude, that the bone metabolism alterations in patients with locally advanced and disseminated PC are pathologic and can be measured fairly. Bisphosphonates use, especially those of the last generation (zoledronic acid) is not only justified but is indicated in the locally advanced cancer to prevent progression of the pathologic bone metabolism caused by age and intense hormonal therapy. It will redice a probability of the expansion of the tumor process into the bones and disease progression. In disseminated PC, decrease in the pathologic bone metabolism will also allow to hamper disease progession and reduce the probability of the pathologic manifestations of the skeleton lesion.